Briefcase

Take Action: Optimizing Equity in Mental Health Care

Launch Date
09/13/2024
Credit Amount
1
Credit Expires
09/13/2027

Faculty

Monica E. Peek, MD, MPH, MSc
Moderator
Ellen H. Block Professor of Health Justice
Vice-Chair for Diversity, Equity and Inclusion
Department of Medicine
University of Chicago
Chicago, IL 
Rakesh Jain, MD, MPH
Clinical Professor, Department of Psychiatry
Texas Tech Health Sciences Center School of Medicine – Permian Basin
Midland, TX
Rakesh Jain, MD, MPH

Rakesh Jain, MD, MPH, is a Clinical Professor in the department of Psychiatry at the Texas Tech Health Sciences Center School of Medicine – Permian Basin in Midland, Texas and in private practice in Austin, Texas. Dr. Jain attended medical school at the University of Calcutta in India. He received his Master of Public Health (MPH) degree from the University of Texas School of Public Health in Houston, where he was awarded a National Institute/Center for Disease Control Competitive Traineeship. His research thesis focused on the impact of substance abuse.

Dr. Jain completed his residency in psychiatry at the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical School at Houston. He then completed a postdoctoral fellowship in research psychiatry at the University of Texas Mental Sciences Institute in Houston. He was awarded the National Research Service Award in support of his postdoctoral fellowship.

Dr. Jain has been involved in over 100 research projects studying the effects of medications on short-term and long-term treatment of depression, anxiety, pain/mood overlap disorders, ADHD, and psychosis in adult and child/adolescent populations. He has presented at the World Psychiatric Congress held in Prague, and at Depression and Pain Forum meetings internationally. He is the author of 55 articles published in various journals and magazines, such as the Journal of Psychiatric Research and  Journal of Clinical Psychiatry, among others, and has presented over 25 original research posters at meetings such as the American Psychological Association (APA), the American College of Neuropsychopharmacology (ACNP), the American Academy of Child and Adolescent Psychiatry (AACAP), the U.S. Psychiatric Congress, and more. He has co-authored six books that range from patient education to cutting-edge neurobiologic findings in psychiatry and mental health. He serves on several advisory boards focusing on drug development and disease state education. He was also recently the Chair of the U.S. Psychiatric Congress, and for several years, has served as a member of the Steering Committee for U.S. Psychiatric Annual Congress. He is a recipient of the Public Citizen of the Year award from the National Association of Social Workers, Gulf Coast Chapter, in recognition of his community and peer education, and championing of mental health issues.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration

Statement of Need

Disparities in mental health diagnosis, treatment, and outcomes significantly affect racial, ethnic, and LGBTQIA+ groups. These populations face barriers such as lower diagnosis rates, inadequate treatment, and poorer outcomes compared to their White, non-LGBTQIA+ counterparts. For instance, Latine patients use mental health care at half the rate of non-Hispanic White patients, and over half of LGBTQIA+ youth who need mental health care do not receive it. Addressing these barriers is critical for improving mental health equity.

In this CME Outfitters BriefCase, part of a collection on health equity, expert faculty will explore strategies to enhance mental health care for underserved populations. Focus will be placed on understanding and mitigating the impact of social drivers of health (SDoH), integrating holistic treatment strategies, and employing team-based approaches. Learners will gain tools to improve diagnosis, treatment, and outcomes for racial, ethnic, and LGBTQIA+ groups, fostering equitable mental health care delivery.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify health inequities in the diagnosis, treatment, and outcomes of patients with mental health disorders
  • Implement actionable strategies to improve health equity in your own practice

Financial Support

Supported by an educational grant provided by Johnson & Johnson.

Target Audience

Primary care or emergency physicians, psychiatrists, psychologists, counselors, social workers, case managers, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, front office staff and administrators, finance staff, executives, support staff, and patients

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.0 contact hours ( 0.01 CEUs) of continuing pharmacy credit (JA0007185-0000-24-068-H01-P).

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 09/13/2027. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr.  Peek reports the following financial relationships:

Advisory Board: Abbott–Diabetes Health Equity Advisory Board (2022)

Dr. Jain reports the following financial relationships:

Advisory Board: Adamas Pharmaceuticals, Inc.; Alkermes; Corium, Inc.; Eisai Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Usona Institute

Consultant: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc.; Alfasigma USA, Inc.; Alkermes; Almatica Pharma, LLC; Axsome Therapeutics, Inc.; Biogen; Boehringer Ingleheim; Corium, Inc.; Cingulate; Eisai Inc.; Evidera; Impel Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Osmotica Pharmaceuticals; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc; Shire Pharmaceuticals; Sumitomo Corporation; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Transcend Therapeutics; and Viatris Inc.

Research Support: AbbVie Inc.; Lilly; Lundbeck; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc. (Allergan); Alkermes; Almatica Pharma, LLC; Axsome Therapeutics, Inc.; Corium, Inc.; Eisai Inc.; Indivior; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Tris Pharma, Inc.; and Viatris Inc.

The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Albert Eubanks, Jr., RN  (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
Keshia Pitt, PhD (Planning Committee)
Jessica Whelan, DNP, APRN, FPMHNP-BC, RN-BC (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

BC-123-091324-57

Take Action: Optimizing Equity in Mental Health Care
Event Date: 09/13/2024
Begin